IRIS
CIMADAMORE, Alessia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 5.521
NA - Nord America 4.366
SA - Sud America 1.491
EU - Europa 1.486
Continente sconosciuto - Info sul continente non disponibili 718
AF - Africa 196
OC - Oceania 5
AN - Antartide 1
Totale 13.784
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.092
SG - Singapore 2.740
BR - Brasile 1.177
CN - Cina 935
HK - Hong Kong 595
VN - Vietnam 508
IT - Italia 483
RU - Federazione Russa 228
FR - Francia 224
DE - Germania 216
KR - Corea 181
BD - Bangladesh 143
AR - Argentina 118
CA - Canada 107
IN - India 102
GB - Regno Unito 88
TG - Togo 69
MX - Messico 62
ID - Indonesia 59
EC - Ecuador 58
IQ - Iraq 43
TR - Turchia 40
CO - Colombia 37
ZA - Sudafrica 36
AT - Austria 32
FI - Finlandia 32
NL - Olanda 29
PL - Polonia 28
PY - Paraguay 28
CL - Cile 27
JP - Giappone 23
ES - Italia 22
PK - Pakistan 22
VE - Venezuela 21
UA - Ucraina 18
JM - Giamaica 17
UZ - Uzbekistan 16
EG - Egitto 15
LT - Lituania 15
IE - Irlanda 14
MA - Marocco 14
TN - Tunisia 14
KE - Kenya 13
SA - Arabia Saudita 13
CR - Costa Rica 12
JO - Giordania 12
HN - Honduras 11
PE - Perù 11
UY - Uruguay 11
AE - Emirati Arabi Uniti 10
SE - Svezia 10
DZ - Algeria 9
GP - Guadalupe 9
NI - Nicaragua 9
TT - Trinidad e Tobago 9
AZ - Azerbaigian 8
EE - Estonia 8
GT - Guatemala 8
SV - El Salvador 8
PH - Filippine 7
PT - Portogallo 7
KZ - Kazakistan 6
NP - Nepal 6
PR - Porto Rico 6
CZ - Repubblica Ceca 5
DO - Repubblica Dominicana 5
IL - Israele 5
LB - Libano 5
SY - Repubblica araba siriana 5
BH - Bahrain 4
ET - Etiopia 4
GR - Grecia 4
MD - Moldavia 4
TW - Taiwan 4
AL - Albania 3
AM - Armenia 3
AO - Angola 3
BO - Bolivia 3
CW - ???statistics.table.value.countryCode.CW??? 3
IR - Iran 3
KW - Kuwait 3
OM - Oman 3
QA - Qatar 3
SN - Senegal 3
TH - Thailandia 3
AU - Australia 2
BB - Barbados 2
BE - Belgio 2
BW - Botswana 2
HU - Ungheria 2
LK - Sri Lanka 2
LV - Lettonia 2
LY - Libia 2
MY - Malesia 2
NZ - Nuova Zelanda 2
PS - Palestinian Territory 2
SC - Seychelles 2
AD - Andorra 1
AQ - Antartide 1
BA - Bosnia-Erzegovina 1
Totale 13.036
Salva come PNG Salva come JPEG
Città #
Singapore 732
San Jose 684
Hong Kong 585
Council Bluffs 580
Beijing 386
Ashburn 355
Boardman 316
Lauterbourg 191
Hefei 183
Ho Chi Minh City 181
Seoul 178
Frankfurt am Main 150
Los Angeles 124
Hanoi 123
São Paulo 98
Dallas 97
Redondo Beach 92
Santa Clara 87
The Dalles 82
Buffalo 79
Lomé 69
Ogden 60
Milan 54
New York 51
Phoenix 51
Rio de Janeiro 42
Rome 41
Naples 31
Guayaquil 30
Mexico City 29
North Bergen 29
Nuremberg 29
Belo Horizonte 27
Brasília 27
Atlanta 23
Helsinki 23
Mumbai 23
Porto Alegre 23
Curitiba 22
Brooklyn 21
Montreal 21
Boston 20
Biên Hòa 19
Orem 19
Remanzacco 19
Chicago 18
Da Nang 18
Ispra 18
Warsaw 18
Haiphong 17
Hyderabad 17
Tokyo 16
Toronto 16
Vienna 16
Amsterdam 15
Bologna 14
Campinas 14
Columbus 14
Denver 14
Johannesburg 14
Philadelphia 14
Ribeirão Preto 14
Salvador 14
Shanghai 14
Codroipo 13
Quito 13
Tashkent 13
Baghdad 12
Dublin 12
Goiânia 12
Houston 12
Las Vegas 12
San José 12
Thái Bình 12
Amman 11
Istanbul 11
Jakarta 11
Maceió 11
Munich 11
Nairobi 11
Santo André 11
Ankara 10
Bogotá 10
Carapicuíba 10
Charlotte 10
Duque de Caxias 10
Franca 10
Guangzhou 10
Hải Dương 10
London 10
Xi'an 10
Asunción 9
Buenos Aires 9
Cape Town 9
Fortaleza 9
Medellín 9
Miami 9
Thái Nguyên 9
Tunis 9
Washington 9
Totale 6.782
Salva come PNG Salva come JPEG
Nome #
News in the classification of WHO 2022 bladder tumors 200
End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer 191
Apalutamide or enzalutamide in castration-sensitive prostate cancer: a number needed to treat analysis 122
SIUrO best practice recommendations to optimize BRCA 1/2 gene testing from DNA extracted from bone biopsy in mCRPC patients (BRCA Optimal Bone Biopsy Procedure: BOP) 120
The uropathologist of the future: getting ready with intelligence for the prostate cancer tsunami 119
Novel Therapeutic Strategies for Metastatic Prostate Cancer Care 119
Giant cell carcinoma of the urinary bladder: Clinicopathologic analysis and oncological outcomes 110
A gender-related dichotomy in bladder cancer 109
Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications 107
Accuracy of the CUETO, EORTC 2016 and EAU 2021 scoring models and risk stratification tables to predict outcomes in high-grade non-muscle-invasive urothelial bladder cancer 107
Nectin-4 Positivity in Genitourinary Malignancies: A Systematic Review 105
Follow-up of the Urethra and Management of Urethral Recurrence After Radical Cystectomy: A Systematic Review and Proposal of Management Algorithm by the European Association of Urology-Young Academic Urologists: Urothelial Carcinoma Working Group 101
Prognostic Significance of Programmed Cell Death-1, Programmed Cell Death-Ligand 1, Programmed Cell Death-Ligand 2, and Fibroblast Growth Factor Receptor 3 mRNA Expression in Bladder Cancer 98
Biological and therapeutic implications of FGFR alterations in urothelial cancer: A systematic review from non-muscle-invasive to metastatic disease 96
Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies 92
Adjuvant immunotherapy in patients with renal cell carcinoma and urothelial carcinoma: A systematic review and network meta-analysis 91
Atlas of PD-L1 for Pathologists: Indications, Scores, Diagnostic Platforms and Reporting Systems 86
Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer 86
Patients ask and pathologists answer: ten questions around prostate cancer grading 84
Prostatic Inflammation 84
How To Report the Minor Component of a High-grade Pattern in Radical Prostatectomy Specimens: Time To Abandon the “Tertiary” Terminology? 83
Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A) 83
Genitourinary tumors: Update on molecular biomarkers for diagnosis, prognosis and prediction of response to therapy 82
Conceptual Analogies Between Multi-Scale Feeding and Feedback Cycles in Supermassive Black Hole and Cancer Environments 81
The Prognostic Significance of Histological Subtypes in Patients with Muscle-Invasive Bladder Cancer: An Overview of the Current Literature 81
Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial 79
Frequent Telomerase Reverse Transcriptase Promoter and Fibroblast Growth Factor Receptor 3 Mutations Support the Precursor Nature of Papillary Urothelial Hyperplasia of the Urinary Bladder 79
Efficacy of Different Bacillus of Calmette-Guérin (BCG) Strains on Recurrence Rates among Intermediate/High-Risk Non-Muscle Invasive Bladder Cancers (NMIBCs): Single-Arm Study Systematic Review, Cumulative and Network Meta-Analysis 79
Digital real-time microscopy of ex-vivo tissues: A novel strategy to control surgical accuracy 78
Agent-Based Learning Model for the Obesity Paradox in RCC 78
Activity of chemokines in prostate and renal tumors and their potential role as future therapeutic targets 77
An update on investigational therapies that target STAT3 for the treatment of cancer 77
Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors 76
Re: Outcomes of Biopsy Grade Group 1 Prostate Cancer Diagnosis in the Danish Population 76
An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer 75
Are liver nested stromal epithelial tumors always low aggressive? 74
PreImplantation Factor immunohistochemical expression correlates with prostate cancer aggressiveness 74
Epigenetic modulations and lineage plasticity in advanced prostate cancer 74
Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B) 74
The most effective but largely ignored target for prostate cancer early detection and intervention 73
Treating prostate cancer by antibody-drug conjugates 73
Real-world data on cabozantinib in previously treated patients with metastatic renal cell carcinoma: Focus on sequences and prognostic factors 73
Histopathology of Prostate Cancer and its Precursors 72
TNM staging towards a personalized approach in metastatic urothelial carcinoma: What will the future be like?-a narrative review 71
Added Clinical Value of Whole-mount Histopathology of Radical Prostatectomy Specimens: A Collaborative Review 71
Towards a new WHO classification of renal cell tumor: What the clinician needs to know-a narrative review 68
Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis 68
Targeted treatment of renal cell carcinoma 68
Adjuvant therapy in renal cell carcinoma: Is it the right strategy to inhibit VEGF? 68
Intraductal Carcinoma of the Prostate: Pathogenesis and Molecular Perspectives 67
Tumors of the Urinary System and Male Genital Organs: 2022 World Health Organization Classification and Multidisciplinarity 67
Spectrum of incipient (or precursor) lesions in the mucosa of the seminal vesicles 66
Epigenetic modifications and modulators in prostate cancer 66
Designing novel immunocombinations in metastatic renal cell carcinoma 65
Uropathologists During the COVID-19 Pandemic: What Can Be Learned in Terms of Social Interaction, Visibility, and Social Distance 65
Chromophobe Renal Cell Carcinoma Aggressiveness and Immuno-oncology Therapy: How to Distinguish the Good One from the Bad One 65
Clinical utility of checkpoint inhibitors against metastatic bladder cancer: overcoming challenges to find a way forward 65
Bone targeting agents in patients with metastatic prostate cancer: State of the art 65
Risk Classification of Bladder Cancer by Gene Expression and Molecular Subtype 65
OUTCOMES OF DIFFERENT PATTERN OF SEMINAL VESICLE INVASION IN PATIENTS TREATED WITH RADICAL PROSTATECTOMY 64
Grading of Chromophobe Renal Cell Carcinoma: Do We Need It? 64
Re: George J. Netto, Mahul B. Amin, Eva M. Compérat, et al. Prostate Adenocarcinoma Grade Group 1: Rationale for Retaining a Cancer Label in the 2022 World Health Organization Classification. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.09.015 64
Prostate cancer in 2021: Novelties in prognostic and therapeutic biomarker evaluation 64
Questioning the prognostic role of BAP-1 immunohistochemistry in malignant pleural mesothelioma: A single center experience with systematic review and meta-analysis 64
PARP Inhibitors and Radiometabolic Approaches in Metastatic Castration-Resistant Prostate Cancer: What’s Now, What’s New, and What’s Coming? 64
The Role of Artificial Intelligence in the Diagnosis and Prognosis of Renal Cell Tumors 64
pT1 high-grade bladder cancer: histologic criteria, pitfalls in the assessment of invasion, and substaging 63
An update on immunotherapy in uro-oncology 63
Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer 63
Re: Timothy D. Jones, Liang Cheng. Histologic Grading of Bladder Tumors: Using Both the 1973 and 2004/2016 World Health Organization Systems in Combination Provides Valuable Information for Establishing Prognostic Risk Groups. Eur Urol 2021;79:489–91 62
Clinical Application of Large Language Models in Generating Pathologic Images 62
Emerging Molecular Technologies in Genitourinary Tumors 62
Re: Gillian Vandekerkhove, Werner J. Struss, Matti Annala, et al. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. Eur Urol 2019;75:667–75: How Does Circulating DNA Reach the Blood Stream? 62
The impact of lymphovascular invasion in patients treated with radical nephroureterectomy for upper tract urothelial carcinoma: An extensive updated systematic review and meta-analysis 62
The molecular characteristics of non‐clear cell renal cell carcinoma: What’s the story morning glory? 62
Narrative review of prostate cancer grading systems: Will the Gleason scores be replaced by the grade groups? 62
Staging and reporting of renal cell carcinomas 62
The pathway of isolated seminal vesicle invasion has a different impact on biochemical recurrence after radical prostatectomy and pelvic lymphadenectomy 61
Digital pathology and COVID-19 and future crises: pathologists can safely diagnose cases from home using a consumer monitor and a mini PC 61
Pathology without microscope: From a projection screen to a virtual slide 61
Surgical checklist adherence across urology expertise levels impacts transurethral resection of bladder tumour quality indicators 61
Molecular classification of bladder urothelial carcinoma using nanostring‐based gene expression analysis 61
Re: Friederike Haidl, David Pfister, Axel Heidenreich. Re: Prostatic Artery Embolization in the Treatment of Localized Prostate Cancer: A Bicentric Prospective Proof-of-Concept Study of 12 Patients. Mordasini L, Hechelhammer L, Diener PA, et al. J Vasc Interv Radiol 2018;29:589–97. Eur Urol 2018;74:525–6: Could Morphologic Changes in Periprostatic Arteries Have an Influence on Prostatic Artery Embolization? 61
Combining radiotherapy with immunocheckpoint inhibitors or CAR-T in Renal Cell Carcinoma 60
An insight on novel molecular pathways in metastatic prostate cancer: A focus on ddr, msi and akt 60
T1 bladder carcinoma with variant histology: pathological features and clinical significance 60
Oncocytic Tumors in the Kidney: A Trifocal Review - Integrated Pathological, Cytopathological, and Molecular Perspectives (Part 1) 59
Renal Cell Carcinoma: genomic landscape and clinical implications 59
Myoid gonadal stromal tumours are characterised by recurrent chromosome-level copy number gains: molecular assessment of a multi-institutional series 58
Resistance to systemic agents in renal cell carcinoma predict and overcome genomic strategies adopted by tumor 58
Quick steps toward precision medicine in renal cell carcinoma 58
Digital and computational transition in the pathology lab: when did it start? 58
Narrative review: Predicting future molecular and clinical profiles of prostate cancer in the United States 57
Artificial intelligence in prostate cancer 57
Editorial: Emerging biomarkers in genitourinary tumors 57
Morphologic spectrum of the epithelial tumors of the male and female urethra 56
Prostate cancer pathology: What has changed in the last 5 years 56
Predictive biomarkers for immunotherapy in the treatment of advanced urothelial carcinoma: Where we stand and where we go 56
Re: Scott Wilkinson, Huihui Ye, Fatima Karzai, et al. Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.03.009: Focus on Intraductal Carcinoma of the Prostate 56
Incorporating Prognostic Biomarkers into Risk Assessment Models and TNM Staging for Prostate Cancer 56
Totale 7.548
Salva come PNG Salva come JPEG
Categoria #
all - tutte 72.133
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 72.133
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/2023628 0 0 0 0 0 0 1 2 512 9 60 44
2023/2024411 25 9 17 10 36 24 10 22 88 112 29 29
2024/20253.489 74 226 38 51 63 162 97 106 341 449 584 1.298
2025/20267.245 502 740 1.030 924 807 625 604 292 258 441 687 335
2026/20272.011 176 401 701 733 0 0 0 0 0 0 0 0
Totale 13.784